- Home
- NURO
NURO
NeuroMetrix Inc.
as 07-26-2024 4:00pm EST
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Upcoming Earnings Alert:
Get ready for potential market movements as NeuroMetrix Inc. NURO prepares to release earnings report on 29 Jul 2024.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 7.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 6.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $7.60 | Next Earning Date: | 07-29-2024 |
| Revenue: | $5,270,210 | Revenue Growth: | -31.36% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of NeuroMetrix Inc. (NURO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horowitz Joshua | NURO | Director | Apr 18 '24 | Sell | $4.58 | 1,000 | $4,580.00 | 23,438 | SEC Form 4 |
Latest NeuroMetrix Inc. News
NURO Breaking Stock News: Dive into NURO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
NeuroMetrix Reports Q1 2024 Business Highlights
Simply Wall St.
3 months ago
NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year
GlobeNewswire
3 months ago
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
GlobeNewswire
4 months ago
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
GlobeNewswire
4 months ago
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
ACCESSWIRE
5 months ago
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
ACCESSWIRE
5 months ago
RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.
ACCESSWIRE
5 months ago
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
Compare NURO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NURO NeuroMetrix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.